Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2017, Article ID 8560827, 8 pages
https://doi.org/10.1155/2017/8560827
Research Article

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis

1Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA
2University of Kentucky College of Medicine, Lexington, KY, USA
3Departments of Oncology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence should be addressed to Chun Li; ude.esac@197lxc

Received 10 August 2017; Accepted 26 October 2017; Published 21 November 2017

Academic Editor: William L. Dahut

Copyright © 2017 Mike Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017. View at Publisher · View at Google Scholar
  2. S. Halabi, C.-Y. Lin, W. K. Kelly et al., “Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 32, no. 7, pp. 671–677, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Nakazawa, C. Paller, and N. Kyprianou, “Mechanisms of Therapeutic Resistance in Prostate Cancer,” Current Oncology Reports, vol. 19, no. 2, 2017. View at Publisher · View at Google Scholar
  4. C. S. Higano and E. D. Crawford, “New and emerging agents for the treatment of castration-resistant prostate cancer,” Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 6, pp. 1–8, 2011. View at Publisher · View at Google Scholar
  5. G. Attard, A. H. M. Reid, T. A. Yap et al., “Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4563–4571, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. Y.-M. Ning, M. Brave, V. E. Maher et al., “U.S. food and drug administration approval summary: Enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer,” The Oncologist, vol. 20, no. 8, pp. 960–966, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Bianchini, D. Lorente, A. Rodriguez-Vida et al., “Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone,” European Journal of Cancer, vol. 50, no. 1, pp. 78–84, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Loriot, D. Bianchini, E. Ileana et al., “Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100),” Annals of Oncology, vol. 24, no. 7, pp. 1807–1812, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Nadal, Z. Zhang, H. Rahman et al., “Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer,” The Prostate, vol. 74, no. 15, pp. 1560–1568, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Badrising, V. van der Noort, I. M. van Oort et al., “Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment,” Cancer, vol. 120, no. 7, pp. 968–975, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. R. J. Van Soest, E. S. De Morrée, C. F. Kweldam et al., “Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer,” European Urology, vol. 67, no. 6, pp. 981–985, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. L. B. Valenca, C. J. Sweeney, and M. M. Pomerantz, “Sequencing current therapies in the treatment of metastatic prostate cancer,” Cancer Treatment Reviews, vol. 41, no. 4, pp. 332–340, 2015. View at Publisher · View at Google Scholar
  13. O. Sartor and S. Gillessen, “Treatment sequencing in metastatic castrate-resistant prostate cancer,” Asian Journal of Andrology, vol. 16, no. 3, pp. 426–431, 2014. View at Publisher · View at Google Scholar
  14. J. S. de Bono, C. J. Logothetis, A. Molina et al., “Abiraterone and increased survival in metastatic prostate cancer,” The New England Journal of Medicine, vol. 364, no. 21, pp. 1995–2005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. H. I. Scher, K. Fizazi, F. Saad et al., “Increased survival with enzalutamide in prostate cancer after chemotherapy,” The New England Journal of Medicine, vol. 367, no. 13, pp. 1187–1197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. C. J. Ryan, M. R. Smith, K. Fizazi et al., “Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study,” The Lancet Oncology, vol. 16, no. 2, pp. 152–160, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. D. F. Penson, A. J. Armstrong, R. Concepcion et al., “Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial,” Journal of Clinical Oncology, vol. 34, no. 18, pp. 2098–2106, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. T. M. Beer, A. J. Armstrong, and D. E. Rathkopf, “Enzalutamide in metastatic prostate cancer before chemotherapy,” The New England Journal of Medicine, vol. 371, no. 5, pp. 424–433, 2014. View at Publisher · View at Google Scholar
  19. B. L. Maughan, B. Luber, R. Nadal, and E. S. Antonarakis, “Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study,” The Prostate, vol. 77, no. 1, pp. 33–40, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. H. I. Scher, S. Halabi, I. Tannock et al., “Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1148–1159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. P. J. A. Cock, T. Antao, J. T. Chang et al., “Biopython: freely available python tools for computational molecular biology and bioinformatics,” Bioinformatics, vol. 25, no. 11, pp. 1422-1423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Viechtbauer, “Conducting meta-analyses in R with the metafor,” Journal of Statistical Software , vol. 36, no. 3, pp. 1–48, 2010. View at Google Scholar · View at Scopus
  24. J. Cortés, J. A. González, M. J. Campbell, and E. Cobo, “A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty,” Journal of Clinical Epidemiology, vol. 67, no. 10, pp. 1172–1177, 2014. View at Publisher · View at Google Scholar
  25. A. Chopra, M. Georgieva, G. Lopes, C. M. Yeo, and B. Haaland, “Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison,” The Prostate, vol. 77, no. 6, pp. 639–646, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. A. W. Partin, M. W. Kattan, E. N. P. Subong et al., “Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update,” Journal of the American Medical Association, vol. 277, no. 18, pp. 1445–1451, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Terada, B. L. Maughan, S. Akamatsu et al., “Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration,” International Journal of Urology, vol. 24, no. 6, pp. 441–448, 2017. View at Publisher · View at Google Scholar
  28. D. Khalaf, M. Annala, K. Beja et al., “A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC),” Journal of Clinical Oncology, vol. 35, 15, 2017. View at Google Scholar
  29. G. S. Palapattu, “Commentary on “AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.” Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38.,” Urologic Oncology: Seminars and Original Investigations, vol. 34, no. 11, p. 520, 2016. View at Publisher · View at Google Scholar
  30. M. Nakazawa, C. Lu, Y. Chen et al., “Serial blood-based analysis of AR-V7 in men with advanced prostate cancer,” Annals of Oncology, vol. 26, no. 9, pp. 1859–1865, 2015. View at Publisher · View at Google Scholar
  31. E. S. Antonarakis, C. Lu, B. Luber et al., “Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer,” JAMA Oncology, vol. 1, no. 5, pp. 582–591, 2015. View at Publisher · View at Google Scholar · View at Scopus